Betibeglogene autotemcel Alternatives Compared
| Betibeglogene autotemcel | Reblozyl (luspatercept) | Luspatercept |
|
|---|
| Betibeglogene autotemcel | Reblozyl (luspatercept) | Luspatercept |
|
|||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Beta Thalassemia. Betibeglogene autotemcel may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Myelodysplastic Syndrome, Beta Thalassemia, Anemia. Reblozyl may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Myelodysplastic Syndrome, Beta Thalassemia, Anemia. Luspatercept may also be used for purposes not listed in this medication guide. |
Related suggestions Beta Thalassemia
|
|||||||
| More about Betibeglogene autotemcel | More about Reblozyl (luspatercept) | More about Luspatercept | ||||||||
| Ratings & Reviews | ||||||||||
|
Be the first to share your experience with this drug. |
Reblozyl has an average rating of 9.2 out of 10 from a total of 6 ratings on Drugs.com. 83% of reviewers reported a positive effect, while 0% reported a negative effect. |
Luspatercept has an average rating of 8.0 out of 10 from a total of 10 ratings on Drugs.com. 60% of reviewers reported a positive effect, while 0% reported a negative effect. |
||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||
|
View all Reblozyl side effects |
View all Luspatercept side effects |
|||||||||
| Drug Class | ||||||||||
| Generic Availability | ||||||||||
|
N/A |
N/A |
N/A |
||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||
|
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Reblozyl prices |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
||||||||
| Dosage Forms | ||||||||||
|
N/A |
|
N/A |
||||||||
| Brand Names | ||||||||||
| Zynteglo |
N/A |
Reblozyl | ||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||
|
N/A |
264 hours |
264 hours |
||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||
| Pregnancy Category | ||||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||
| Drug Interactions | ||||||||||
|
A total of 44 drugs are known to interact with Betibeglogene autotemcel:
|
A total of 2 drugs are known to interact with Reblozyl:
|
A total of 2 drugs are known to interact with Luspatercept:
|
||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||
| Disease Interactions | ||||||||||
| First Approval Date | ||||||||||
|
N/A |
November 08, 2019 |
November 08, 2019 |
||||||||
| WADA Class View classifications | ||||||||||
|
N/A |
||||||||||
| More Information | ||||||||||
| Patient Resources | ||||||||||
| Professional Resources | ||||||||||
| Related Treatment Guide | ||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.